GSK announces Phase III data for TYKERB/TYVERB® (lapatinib) in combination with chemotherapy for advanced HER2-positive gastric cancer

GSK announces Phase III data for TYKERB/TYVERB® (lapatinib) in combination with chemotherapy for advanced HER2-positive gastric cancer

GlaxoSmithKline (GSK) plc today announced that its study of TYKERB/TYVERB®(lapatinib) in combination with chemotherapy in patients with HER2-positive advanced gastric cancer did not meet the primary endpoint of improved overall survival (OS) compared to chemotherapy alone. The median OS for patients in the lapatinib plus chemotherapy group was 12.2 months compared to 10.5 months for patients randomised to placebo plus chemotherapy (HR=0.91; 95% CI: 0.73, 1.12; p=0.3492). There were no new safety signals identified in this trial.

This was a randomised, double-blinded Phase III study of lapatinib in combination with chemotherapy (oxaliplatin and capecitabine) compared to chemotherapy plus placebo in patients with HER2-positive advanced gastric cancer in the first line treatment setting. The primary endpoint was overall survival and secondary endpoints included progression-free survival, response rate and duration of response. Median progression-free survival for patients in the lapatinib plus chemotherapy group was 6.0 months and 5.4 months for those in the chemotherapy alone group. Response rate was 53% for patients in the lapatinib plus chemotherapy group and 39% for those in the chemotherapy alone group. In the lapatinib plus chemotherapy group, the duration of response was 7.3 months compared to 5.6 months in the placebo plus chemotherapy group.

The most commonly reported (≥ 20%) adverse events (AE) in the lapatinib plus chemotherapy group were diarrhoea (58%), nausea (49%), vomiting (44%), decreased appetite (41%), fatigue (24%), rash (21%) and palmar-plantar erythrodysesthesia (20%). The most common AEs in the chemotherapy alone group were nausea (43%), vomiting (36%), decreased appetite (32%), diarrhoea (29%), fatigue (21%) and peripheral neuropathy (20%). Serious adverse events (SAEs) reported in more than 2% of patients in the lapatinib plus chemotherapy group were diarrhoea (6%), vomiting (3%), anemia (2%), dehydration (2%), nausea (2%). Vomiting (2%) was the most common SAE reported in the chemotherapy group.

TYKERB/TYVERB (lapatinib) is not approved or licensed anywhere in the world for the treatment of HER2-positive advanced gastric cancer.

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.